(EL SEGUNDO, Calif.) July 7, 2020 – Radiology Partners (RP), the leading radiology practice in the U.S. today unveiled COVID-19 reporting updates to recoMD, its proprietary artificial intelligence tool that provides real-time, evidence-based practice recommendations to radiologists.
RecoMD uses natural language processing to interpret radiologists' reports and combines that information with metadata about the patient and exam to provide the appropriate, evidence-based best practice recommendations to the radiologists in real time. RecoMD reduces reporting variability to help limit unnecessary examinations. The tool also assists radiologists in identifying which patients need follow-up imaging to ensure important findings like cancer and aortic aneurysms are not being missed.
By adding COVID-19 reporting guidelines endorsed by the American College of Radiology (ACR), Radiological Society of North America (RSNA), and Society of Thoracic Radiology (STR) into recoMD, RP is able to assist radiologists with a disease in which our understanding is rapidly evolving. Specifically, recoMD helps radiologists characterize and report findings of COVID-19 in a framework that improves clarity. "RecoMD was created to make it easier to practice medicine better," said Nina Kottler, MD, MS, Radiology Partners. "By supporting adherence to best practices, recoMD helps improve health outcomes, reduce unnecessary imaging and greatly enhance both the patient and physician experience. Such enhancements are especially imperative during a global health pandemic."
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
RecoMD immediately increased adherence to evidence-based best practices across RP. The first RP practice in which recoMD was implemented improved clinical guideline adherence by up to 83%. Specifically, guideline adherence increased from 75% to 100% on ovarian cysts, from 61% to 92% on abdominal aortic aneurysms and from 54% to 99% on incidental thyroid nodules.